Impact of COVID-19 among people who use drugs: A qualitative study with harm reduction workers and people who use drugs

Fiona N. Conway1*, Jake Samora1, Katlyn Brinkley1, Haelim Jeong2, Nina Clinton3 and Kasey R. Claborn1,4,5

Abstract

Background: Fatal drug overdoses in the USA hit historical records during the COVID-19 pandemic. Throughout the pandemic, people who used drugs had greater odds of contracting COVID-19, increased drug use due to COVID-related stress, and heightened levels of anxiety and depression. This qualitative study examined the specific ways the pandemic negatively impacted people who use drugs.

Methods: Qualitative interviews with 24 people who use drugs and 20 substance use harm reduction workers were conducted. Data from the qualitative interviews were analyzed using applied thematic analysis to identify emergent themes based on the a priori research goals.

Results: Thematic analysis identified several common experiences during the pandemic among people who use drugs. These included mental distress due to financial strain and social isolation; increased drug use; increased risky drug-seeking and use behaviors due to changes in the drug markets; and reduced access to harm reduction, treatment, and recovery support services.

Conclusions: Our study highlighted critical systemic failures that contributed to the rise in overdose deaths during the COVID-19 pandemic. Addressing these challenges through policy reform and improved funding models will ensure the sustainability of harm reduction services and increase access to substance use treatment among highly vulnerable people who use drugs.

Keywords: COVID-19, Pandemic, Drug use, Harm reduction, People who use drugs, Substance use disorder

Background

The COVID-19 pandemic is devastating the mental and physical health of millions of people across the globe [1, 2]. Everyone is at risk of contracting the illness, but some groups of people experience exponential negative effects due to membership in particularly vulnerable populations. One such group that has been severely neglected throughout the COVID-19 response are people who use drugs [PWUD]. In the USA during 2020, 93,000 people died from drug overdoses—a 30.9% increase from 2019 and the highest change in a 12-month period [3]. Steadily emerging research indicates that poor health outcomes associated with substance use have been particularly amplified during the COVID-19 pandemic. A retrospective study conducted on electronic health records found that individuals with a substance use disorder (SUD) were at much greater odds of contracting COVID-19, and died at a rate 1.5 times greater than those without SUD diagnoses [4]. Death either from drug overdose or from complications of COVID-19 is the most troubling outcome for PUWD during the pandemic, but other consequences of the
global health crisis are also important. COVID-related stress has been associated with increases in drug use [5]. This rise in use of illicit substances, including opiates and psychostimulants [6], has contributed to an increase in numerous sequelae associated with SUD. Also, increased loneliness and decreased social connectedness during the pandemic has led to heightened levels of anxiety and depressive symptomatology among PWUD [7].

At the same time that PWUD are experiencing negative health outcomes from the pandemic, their access and engagement in treatment has been severely disrupted. Qualitative research about the experiences of PWUD during COVID-19 has been invaluable in providing a lens into their lived experience. One study that provided findings from interviews with directors of residential SUD treatment centers highlighted negative impacts of the pandemic, including less client engagement in treatment, reduced resources and staff, and challenges using telehealth services [8]. Other studies have uncovered that during the pandemic PWUD had exceeding difficulty accessing healthcare-based services (e.g., medication assisted treatment clinics, primary care), and community-based services (e.g., recovery groups), and harm reduction services (e.g., syringe exchange programs, Narcan distribution etc.) [9, 10]. In many instances, harm reduction organizations moved to virtual mediums or reduced availability, creating barriers for PWUD in accessing services [11]. Harm reduction services are critical for PWUD who are not engaged in treatment or at the stage of recovery. Services are focused on reducing the harms associated with drug use through programs such as clean needle exchange, naloxone distribution, wound care, safe use education, and other strategies [12, 13]. It is therefore imperative that harm reduction services be readily available and accessible during a global health crisis.

Recent qualitative studies have made significant contributions to our understanding of the impact of the COVID-19 pandemic on the physical and mental health of PWUD. Almost all of them, however, have only used harm reduction workers (HR) or treatment providers as the source of their information. Thus, their ability to truly capture the experiences of PWUD is limited because their findings are based on secondary sources (providers and service workers), not primary sources (PWUD). None of the studies, to our knowledge, have conducted concurrent interviews of HR and PWUD from the same service area. Our study aimed to address this gap in the literature. We present findings from interviews with both PWUD and HR about the impact of COVID-19 on mental health and substance use among PWUD as well as the impact on harm reduction and treatment services.

Methods
This qualitative study examined the specific ways the pandemic negatively impacted people who use drugs. Results from this study are based on a larger parent study designed to understand perspectives on overdose response and prevention efforts in Texas and to develop and implement a digital platform to improve overdose reporting [14]. As the COVID-19 pandemic emerged as a global health crisis, we anticipated that it would affect drug use and overdose risk. As such, we added pandemic-related questions to our interview guide for the parent study.

Participants
Our sample included a subset of participants from the parent study. The parent study included key stakeholders from a variety of target groups including PWUD, harm reductionists, first responders, and overdose prevention experts. For the purposes of this study, we included data from the harm reductionists and PWUD participants. This sample subset answered interview questions created for the parent study as well as the COVID-19-related questions. Participants (n = 24 PWUD; n = 20 HR) were recruited from four counties in Texas including El Paso, Bexar, Travis, and Williamson counties (see Table 1 for participant demographics). We employed an opportunity sampling approach. Recruitment methods included in-person conversations at harm reduction organizations (when permitted), flyers, e-mails, telephone calls, snowball sampling, social media advertising, web-postings, word of mouth and use of our Community Advisory Boards. All potential participants were screened with a short survey either via phone call or email by a trained research assistant. The inclusion criteria for HR participants included: (1) eighteen years or older; (2) volunteer or paid staff member for a harm reduction organization; and (3) ability to read and speak in English. The inclusion criteria for PWUD participants included: (1) eighteen years or older; (2) used opioids or stimulants in the past three months, (3) resides in Texas, and (4) ability to read and speak in English. The exclusion criteria for all participants included: the inability or unwillingness to provide consent and being actively intoxicated, suicidal, or psychotic. If a potential participant fit the inclusion criteria, informed consent was provided and obtained.

Data collection
Trained research assistants conducted qualitative interviews that lasted 60 to 90 min. Participants were compensated $30 for their time. Interviews were conducted by video conference or telephone with two trained researchers. In these interviews, we addressed the following research questions: (1) How does COVID-19 impact
mental health and substance use among people who use drugs? (2) How does COVID-19 impact harm reduction and treatment services? Participants were assigned a unique ID number, and after each interview was completed, the audio recordings were transcribed verbatim by a professional transcription agency. Transcripts were cleaned of all personal identifying information.

Data analysis
Data from the qualitative interviews were analyzed using applied thematic analysis, which was selected for its flexibility and systematic approach in analyzing text-based qualitative data [15]. Originally, the team identified emergent themes based on the a priori research goals. Based on these major themes, a working codebook and framework matrix was generated. The codebook went through multiple iterations due to emerging data in the transcripts that were relative to our research objectives. Data analysis involved six trained coders (two clinical research associates and four research assistants) by means of a reflexive analysis approach. Each transcript was assigned to two members of the team to code independently using the codebook. Once both members completed their coding process, the members met, while using the reflexive team approach to resolve inconsistencies in coding until they reached a consensus and finalized the coded transcript.

Results
Thematic analysis of the interviews produced key insights about the mental health and drug use behavior of PWUD during the pandemic. Important themes emerged about (a) increased mental strain, (b) increased drug use, (c) changes in the drug market, and (d) engagement in risky drug seeking and use behavior. Participants also reported difficulty obtaining multiple types of services including (e) treatment, (f) recovery support, and (g) harm reduction. The end of each quote is labeled PWUD or HR to designate which category of participant provided the statement.

Increased mental health strains
Participants reported experiencing heightened levels of stress due to mounting financial uncertainty with the economic conditions brought on by COVID-19. Many PWUD (n=14) reported losing jobs, losing housing, and increased debt from borrowing money from friends. Others commented on job loss among family members who they rely on for financial support. One participant noted, “my dad is in the entertainment industry… but there’s no events right now… he would supplement his income substitute teaching, but schools are closed” (PWUD). Some (n=7) made a clear connection between financial strain and mental distress among PWUD in their service area stating, “people losing their jobs… it’s caused a lot of stress” (HR). One PWUD also relayed that they experienced anxiety about their lack of insurance should they need to be hospitalized due to contracting COVID. In addition, participants reported that social distancing and isolation have also taken a heavy toll on mental well-being. A participant remarked,

| Table 1 Participant characteristics |
|-----------------------------------|
|                                    |
| Harm reductionists (n = 20) | People who use drugs (n = 24) |
| N | % | N | % |
|---|----|---|----|
| Age | Median (IQR) | 35 (29–50) | 36 (29–43) |
| Gender at birth | Female | 10 | 50 | 13 | 54.2 |
| | Male | 10 | 50 | 11 | 45.8 |
| | Intersex | – | – | – | – |
| Gender identity | Male | 9 | 45 | 13 | 54.2 |
| | Female | 9 | 45 | 11 | 45.8 |
| | Transgender (FTM) | 1 | 5 | – | – |
| | Transgender (MTF) | – | – | – | – |
| | Non-binary | 1 | 5 | – | – |
| | Other | – | – | – | – |
| | Unknown | – | – | – | – |
| | Prefer not to answer | – | – | – | – |
| Sexual orientation | Gay/Lesbian | 2 | 10 | 1 | 4.2 |
| | Straight/Heterosexual | 11 | 55 | 21 | 87.5 |
| | Bisexual | 5 | 25 | 2 | 8.3 |
| | Other | 3 | 15 | – | – |
| | Prefer not to answer | – | – | – | – |
| Race | Asian | 2 | 10 | – | – |
| | American Indian/Alaskan Native | 1 | 5 | – | – |
| | Black/African American | 2 | 10 | 1 | 4.2 |
| | Pacific Islander/Native Hawaiian | – | – | – | – |
| | White/Caucasian | 14 | 70 | 20 | 83.3 |
| | Other | 4 | 20 | 5 | 20.8 |
| Ethnicity | Hispanic or Latino | 8 | 40 | 10 | 41.7 |
| | Not Hispanic or Latino | 11 | 55 | 13 | 54.2 |
| | Prefer not to answer | 1 | 5 | 1 | 4.2 |
“I have anxiety…[I] was diagnosed with depression…it’s made it a lot worse having to stay at home. Not being able to go do things” (PWUD).

Increased drug use
Participants reported that the pandemic has triggered increased drug use due to financial stress, fear of contracting COVID, and boredom due to joblessness and isolation from friends and family. One PWUD remarked “I definitely have been using drugs more to cope with [stress]. More self-medicating than I have in a long time” (PWUD). Another noted “I’m definitely using more…because I don’t really have anything to do all day. I mean, all day I’m just kind of sitting at home” (PWUD). Two participants reported that people who did not experience joblessness, but transitioned to working at home also increased drug use. One person commented on their brother’s drug use saying, “having to be at home now and working off his computer…he has too much time…[he] just sits there in his house and get[s] high” (PWUD). Results from interviews with harm reduction workers corroborated reports from PWUD about increased drug use. Workers highlighted the connection between increased drug use and pandemic-related mental health challenges. One of them stated, “there’s just a lot more use individually, and a lot more use within groups…not having work, being nervous, the anxiety, it’s just leading them to use more than usual” (HR). Increases in drug use related to COVID-19 was described as highly prevalent from both PWUD and harm reduction workers, illustrating an added challenge to the already disadvantaged position of this vulnerable population.

Changes in the drug market
Themes emerged pertaining to the drug supply chain including reduced supply, increased demand, decreased quality and purity of the drug supply, and a rise in prices of drugs. COVID-19 prompted significant disruptions to the drug supply chain. One explanation for the decrease in availability is that dealers have less supply. A harm reduction worker noted that “The [drug] supply is dryin’ up…there’s less product out there in the community” (HR). Another reason for the decrease in supply is the reduction in the number of people selling drugs. A worker explained, “a couple of major drug dealers have already closed shop because they … don’t have access to [suppliers]” (HR). Additional participants provided other insights about the reasons for the decrease in supply. A PWUD stated, “well, with the borders [between Mexico and the USA] being shut down, there’s not as much drugs coming across” (PWUD). One consequence of the disruption in the supply chain was the increase in drug prices. In one instance, both harm reduction workers and PWUD mentioned increased prices for the same type of drug. A harm reduction worker stated, “there’s been crazy spikes in prices, particularly for the methamphetamine, prices have gone up way high” (HR). This observation was corroborated by several PWUD (n=7). One of them stated, “methamphetamines are twice the price that they used to be” (PWUD). One unexpected outcome of the changes in the drug market was that decreased supply and inflation in prices resulted in decreased consumption for a few individuals (n=2). One participant reported “tryin’ to, like, you know, squeeze a whole lot more out of a dose than I normally would” (PWUD). Another remarked, “it becomes a point where, you know, it’s not really available to the point where it’s, you know, harder to get than I wanna put effort into” (PWUD).

Increased risky behaviors
Due to the low supply and increased price of illicit drugs, harm reduction workers expressed added concerns about the increase in risky substance use behaviors. One behavior is switching the drug of choice. One harm reduction worker remarked, “we’re seeing drugs of choices, and reliable dealers having to be exchanged for questionable substances” (HR) and a PWUD shared “I would say it’s changed… the type of drugs I use…cocaine’s expensive and like, ketamine’s expensive as hell” (PWUD). This highlights how use of specific, more relatively expensive drugs may have decreased, but substance use among individuals increased in possibly riskier ways due to unfamiliarity with different substances. Harm reduction workers also reported that clients in their service areas were engaging in isolated use, putting them at higher risk for fatal overdose. One worker stated, “A lot of people are using alone because of social distancing…if something happens…there’s not going to be anybody there to help them out with Narcan [overdose reversal drug] or, like, any other form of resuscitation methods” (HR). Another worker remarked on hesitation from drug suppliers to allow PWUD into their homes:

I’ve seen increased paranoia amongst [dealers], as well, where they’re hesitant to allow people into their apartments. They’re hesitant to allow people into their area because they don’t know if they’ve been infected [with COVID].…[before the pandemic] a lot of the overdose reversals I see taking place, happen in the supplier’s home but one person, in particular, is like, ‘I don’t really know if I want people, like, hanging out here right now.’ And we know that means there’s an increased likelihood of them…using in solitude, by themselves. (HR).

The impact on safe use practices by COVID-19’s social distancing and quarantine requirements adds to the
potential risk of overdose, exacerbating the already present risks of overdose when using substances. In addition to the risks associated with switching drugs, and using drugs alone, workers also expressed concerns about increased risky drug-seeking behaviors. Multiple harm reduction workers shared concerns that people in their service area could be compromising their safety to obtain drugs. One worker shared, “[PWUD] have to take riskier chances to get money...you can't panhandle like a lot of people do...there’s just nobody out on the streets [because of COVID] ...so you’re seeing, uh, riskier behaviors” (HR). Another noted the dangers of PWUD seeking drugs in locations outside of their usual areas remarking, “they're gonna go outside their community to get what they need, you know, and that puts them at higher risk of not only, you know, COVID-19, but also police persecution, [and] overdose” (HR).

Reduced access to treatment and recovery support
COVID-19 has an undeniable impact on the mental health and substance use patterns of PWUD and the same is true for harm reduction, treatment, and recovery support services. Participants shared that there was an increased demand for services. A harm reduction worker reported:

Some people who I’ve talked to recently have reported almost wanting to... try to get clean during this time... may as well try to find a detox facility right now or find medication assisted treatment, because either the [drug] prices are so high, or it’s so difficult to obtain. (HR)

Although demand for services increased, participants reported experiences of disruptions and reduced access to providers and resources, including phone lines being rerouted, programs shutting down, and clinics being unresponsive. One participant who was enrolled in a methadone program described their difficulty reaching a caseworker expressing: “now they’ve changed his number where I can’t call him...I would call him like once a week and tell him how I was...how I’m supposed to get in touch with him? I don’t like it at all” (PWUD). This lack or access also affected PWUD who needed recovery support services. Participants indicated that the pandemic had “pretty much stopped AA meetings around, you know, everywhere [making it] kinda difficult for people who are in recovery...[to] maintain sobriety, you know?” (PWUD). As PWUD rely on resources such as support groups and rehab/detox services to sustain recovery, these pandemic-related frustrations caused major disruptions to their recovery path. One participant described the difficulty of getting treatment for a friend: “We tried to get him into a rehab...anybody that we could get to answer the phones, they were like, yeah, we don’t know what’s going on, just because of this whole COVID thing. We’re not getting anybody in anywhere right now.” (PWUD).

Reduced access to harm reduction services
In addition to lack or disruption of treatment and recovery services, PWUD reported on the diminished availability of harm reduction services. One participant remarked on the lack of access to these services and the resources provided, saying that they “went to a [homeless] camp that's primarily heroin use...[people] said that no [harm reduction worker has] been out there for months. They don’t have access to syringes or anything or Narcan” (PWUD). Another participant who disclosed that they were engaged in harm reduction services provided by the same organization for over two year remarked:

[The organization] had a van that would go and meet people five days a week at two locations... but once all this [i.e., the pandemic] started... they immediately cut the five days off, and I think there was a week or two that they didn't do anything. (PWUD)

Harm reduction workers also shared their experiences and frustrations with their diminished capacity to provide services. They reported rapid and drastic changes in their provision of services and in systemic policy changes due to public health safety measures in response to the pandemic, including relocating service sites, reducing operating hours, suspending services, and stopping face-to-face interactions. One worker remarked, “I cannot go out into the field. I haven't done outreach...I haven't seen my patients” (HR). Mitigation of in-person contact was especially damaging to service provision for people living without shelter or homes. One worker shared that before the pandemic workers “used to just go into the [homeless] encampments and talk to everybody that [they] could and now...going into the homeless camp and having a seat and a discussion with folk...that's no longer happening” (HR). Harm reduction workers also shared that there was negative response in their communities regarding their fieldwork. One worker explained:

[We] encountered [opposition] from some of the communities where we normally set up because there's an increased sensitivity to seeing, all of a sudden, large crowds of people with limited access to PPE [personal protective equipment] hovering in areas, in neighborhoods. (HR)

Another worker expressed frustration at systemic changes stemming from competing and often conflicting guidelines from local and state public health agencies saying, “I think that a lot of harm reduction organizations
Discussion

Fatal overdoses in the USA hit historic records during the COVID-19 pandemic, and the healthcare system failed to adequately support the needs of people who use drugs during this global crisis. During the past two years, there have been major advancements in the availability of protective vaccines and some people are feeling less isolated due to loosened official restrictions on social contacts. Still many COVID-related stressors remain. Unemployment is a persistent issue, and many people are still working from home part-time or full-time. In addition, fear of contracting COVID due to variants—such as Delta and Omicron—remains. This fear can cause increased anxiety and influence many people to self-isolate despite changes to government policies or recommendations from the Center for Disease Control. Understanding factors associated with COVID-related risky drug seeking and use behaviors, as well as understanding pandemic-related stressors that contribute to overdose risk, remains a critical area of study towards developing strategies to mitigate the negative sequelae of the COVID-19 pandemic among people who use drugs.

Our findings regarding the negative impact of the pandemic on PWUD and their access to services are supported by qualitative studies conducted in various global locations. One common theme is reports of changes in the drug market including reduced supply [16–18], increased prices [16, 19], and decreased quality/purity [20]. These market changes as well as pandemic-related social contact restrictions precipitated increases in risky drug use such as using in isolation [17], sharing injection equipment [18], and switching drug type [18, 21]. Our studies and others also highlighted critical systemic failures exemplified by the disruption of prevention, harm reduction, and treatment services including temporary closures [22, 23], capacity restrictions at harm reduction sites [17], and less access to safe injection equipment [24, 25]. There are a few notable exceptions to the consensus view that the COVID-19 pandemic negatively impacted drug markets, drug use behaviors, and service provision. PWUD in Switzerland reported relatively stable supply, prices, and purity of illegal substances [26] and harm reduction workers and PWUD in Vietnam reported no increase in the sharing of needles for heroin injection [27]. Also, studies in Scotland [28] and New Zealand [29] featured reports that pandemic-related changes to service provision in their geographic area improved access overall due to the convenience and reduced structural barriers (e.g., transportation difficulties) of telehealth delivery and relaxed legal and policy restrictions.

Although the negative impact of the COVID-19 pandemic on drug overdose risk and service provision is evident, several studies document successful efforts—by organizations and among PWUD community members—to ensure safe substance use and continuity of services. One example is the transition of the overdose risk-reducing practice of in-person peer supervision of drug consumption to remote supervision via voice calls, texts, video conferences, and social media apps [23]. Others include policy changes to allow telemedicine visits for buprenorphine prescriptions [30], telegram instant messaging for education on treatment of minor injection drug use complications [31], and transition from visits on-foot to car-based delivery of harm reduction supplies to people who are experiencing homelessness [30]. Relaxed guidelines and mandates such as suspension of

like mine were really impacted by statewide orders that superseded local orders]” (HR). Harm reduction services being difficult to access despite high demand, increased risky use behaviors. Health and safety for injection drug users were at greater risk. One participant reported, “trying to make [syringes] last longer, and the longer I use them, the duller they get, and the more that it ends up really hurting, and it ends up like tearing, you know” (PWUD). Although the pandemic negatively impacted the availability and quality of harm reduction services, one worker viewed the need for rapid organizational change as an opportunity for positive public policy changes stating:

“There’s some major regulatory changes...we’re having to coordinate in ways that we never thought of before, and I think what’s gonna come as a result of this is a realization that a lot of the regulations that have been in place actually are unnecessary and actually are contributing to mortality. (HR)

Reduced services that resulted from COVID-19 increased risky behaviors and has drawn attention to the importance of harm reduction work in local communities. Despite the organizational and systemic changes caused by the pandemic, some harm reduction workers (n=5) commented on their steadfast commitment to providing services to people in their communities. One worker said:

“A lot of [staff] are still willing to, you know, go in every day and do the work that needs to be done. Because people in harm reduction are very passionate about what they do...the pandemic is a new situation for sure, but, you know, we’ve done it...whether or not it’s safe to do sometimes. Like lines [i.e., COVID safety guidelines] have been crossed for sure. But I think that’s just because, the drive, and the passion. (HR).”
in-person urine drug screening [32, 33], and transition from in-person to curbside or take-home opioid substitution therapy [20, 33–35] also facilitated service continuity. The most documented approach used to adapt to the pandemic social contact restrictions was the transition to web or telephone service delivery [36, 37]. Studies also noted, however, that PWUD with limited access to internet or reliable cell phone data plans were disadvantaged and lacked the ability to access telehealth service options [29, 35, 38]. Some participants also noted difficulty establishing therapeutic alliance and rapport remotely [32, 39]. The preponderance of research evidence supports the consensus that the COVID-19 pandemic negatively impacted the lives of PWUD, but also that service providers and harm reduction workers found creative ways to support continuity of services. Ensuring uninterrupted harm reduction, treatment, and recovery services, particularly during a pandemic requiring social isolation at a time of immense uncertainty and stress, is a critical public health strategy to prevent fatal overdoses.

Limitations
These findings should be taken in light of its limitations. Our sample was primarily White and heterosexual, limiting extrapolation of findings to sexual orientation and gender minority groups and other racial/ethnic populations. Also, our participants were PWUD and harm reduction workers located in Texas. The political infrastructure and the fact that Texas borders Mexico may limit the generalizability of these findings to other geographic locations. Even so, a strength of our study is the reciprocal corroboration of statements between PWUD and harm reduction workers. As such, future study designs should include data collection from multiple categories of stakeholders and also seek to quantitatively examine the factors identified through our qualitative methods to inform frequency and impact among this population. Finally,

Conclusion
This qualitative study identified key factors that should be considered in disaster planning and risk mitigation strategies for future pandemics. More importantly, it highlighted key infrastructure challenges inherent in the addiction prevention and treatment continuum. These challenges need to be addressed through policy reform and improving funding models to improve sustainability of harm reduction services and increase access to substance use treatment among highly vulnerable people who use drugs.

Abbreviations
PWUD: People who use drugs; HR: Harm reduction worker.

Author contributions
FC led the conceptualization and writing of the manuscript. JS, KB, HJ, and NC completed the data analyses. KC conceived and supervised the study and obtained funding. All authors wrote sections of the manuscript, read, and approved the final manuscript.

Funding
This study was supported by Texas Targeted Opioid Response, a public health initiative operated by the Texas Health and Human Services Commission through federal funding from the Substance Abuse and Mental Health Services Administration (SAMHSA) grant award number H79TI081729. Dr. Claborn’s effort is also supported by NIDA K23DA039037 and R34DA041237. The content of this study does not represent the official view of SAMHSA, the Texas Health and Human Services Commission or the National Institutes of Health.

Declarations
Ethics approval and consent to participate
We received IRB approval (IRB # 2019-11-0056) prior to any study activities from The University of Texas at Austin. All participants provided verbal informed consent.

Consent for publication
Consent for publication was included in the informed consent process prior to each interview.

Competing interests
The authors declare that they have no competing interests.

Author details
1 The University of Texas at Austin Steve Hicks School of Social Work, 1925 San Jacinto Boulevard, Austin, TX 78712, USA. 2 School of Social Work, The University of Alabama, 670 Judy Bonner Drive, Tuscaloosa, AL 35401, USA. 3 Department of Psychological Sciences, Texas Tech University, 2700 18th St, Lubbock, TX 79410, USA. 4 Department of Psychiatry, The University of Texas at Austin Dell Medical School, 1601 Trinity Street, Bldg B, Austin, TX 78701, USA. 5 Addiction Research Institute, The University of Texas at Austin Steve Hicks School of Social Work, 3001 Lake Austin Boulevard, Suite 1.204, Austin, TX 78703, USA.

Received: 29 January 2022 Accepted: 14 June 2022 Published online: 02 July 2022

References
1. Lange KW. Coronavirus disease 2019 (COVID-19) and global mental health. Glob Heal J. 2021;5(1):31–6.
2. Reid MI, Abdool-Karim Qu, Geng EJ, Goosby E. How will COVID-19 transform global health post-pandemic? Defining research and investment opportunities and priorities. PLoS Med. 2021;18(3): e1003564. https://doi.org/10.1371/journal.pmed.1003564.
3. Ahmad FB, Rossen LM, Sutton P. Provisional drug overdose death counts. Centers for Disease Control. 2019 [cited 2021 Oct 27]. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm.
4. Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2021;26(1):30–9.
5. Taylor S, Paluszek MM, Rachor GS, McKay D, Asmundson GJG. Substance use and abuse, COVID-19-related distress, and disregard for social distancing: a network analysis. Addict Behav. 2021;114:106754.
6. Bart G, Wastvedt S, Hodges JS, Rosenthal R. Did drug use increase following COVID-19 relaxation of methadone take-out regulations? 2020 was a complicated year. J Subst Abuse Treat. 2022;133: e108590.
7. Horigian VE, Schmidt RD, Feaster DJ. Loneliness, mental health, and substance use among US young adults during COVID-19. J Psychoactive Drugs. 2021;53(1):1–9.
8. Pagano A, Hosakote S, Kapiteni K, Straus ER, Wong J, Guidysh JR. Impacts of COVID-19 on residential treatment programs for substance use disorder. J Subst Abus Treat. 2021;123:108255.

9. Gleason E, Nolan NS, Marks LR, Habrock T, Lang SY, Durkin MJ. Barriers to care experienced by patients who inject drugs during the COVID-19 pandemic: a qualitative analysis. J Addict Med. 2021;16(2):e133.

10. Seaman A, Leichtling G, Stack E, Gray M, Pope J, Larsen JE, et al. Harm reduction and adaptations among PWUD in rural Oregon during COVID-19. AIDS Behav. 2021;25(3):1331–9.

11. Wilkinson R, Hines L, Holland A, Mandler S, Phipps E. Rapid evidence review of harm reduction interventions and messaging for people who inject drugs during pandemic events: implications for the ongoing COVID-19 response. Harm Reduct J. 2020;17(1):1–10.

12. Beirness DJ, Notarandrea R, Jessemann P, Ronen M. Reducing the harm of "harm reduction." Clin Pharmacol Ther. 2008;83(4):523–5.

13. Tatarsky A. Harm reduction psychotherapy: extending the reach of traditional substance use treatment. J Subst Abuse Treat. 2003;25(4):249–56.

14. Claborn K, Creech S, Whittfield Q, Parra-Cardona R, Daugherty A, Benzer J. Ethical by design: engaging the community to co-design a digital health ecosystem to improve overdose prevention efforts among highly vulnerable people who use drugs. Front Digital Health. 2022;4. https://www.frontiersin.org/articles/10.3389/fdigi.2022.880489/full.

15. Guest G, MacQueen K, Namey E. Applied thematic analysis. Washington, DC: Sage Publications; 2014.

16. Bolinski RS, Walters S, Salisbury-Afshar E, Ouellet LJ, Jenkins WD, Amirol E, et al. The impact of the COVID-19 pandemic on drug use behaviors, fentanyl exposure, and harm reduction service support among people who use drugs in rural settings. Int J Environ Res Public Health. 2022;19(4):2230.

17. Galarneau LR, Hilbert J, O’Neill RZ, Buxton JA, Scheuermeier FX, Dong K, et al. Experiences of people with opioid use disorder during the COVID-19 pandemic: a qualitative study. PLoS ONE. 2021;16(7):e0255396. https://doi.org/10.1371/journal.pone.0255396.

18. Oitativhili D, Mgebrishvili T, Beselaa A, Vardanashvili I, Dumchev K, Kiriazova E, et al. The impact of the COVID-19 pandemic on illicit drug supply, drug-related behaviour of people who use drugs and provision of drug related services in Georgia: results of a mixed methods prospective cohort study. Harm Reduct J. 2022;19(1):1–15. https://doi.org/10.1186/s12954-022-00601-z.

19. Ali F, Russell C, Naef F, Rehm J, LeBlanc S, Elton-Marshall T. Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: a national qualitative assessment in Canada. Int J Drug Policy. 2021;93:103237. https://doi.org/10.1016/j.drugpo.2021.103237.

20. Kesten JM, Holland A, Linton MJ, Family H, Scott J, Horwood J, et al. How has the COVID-19 epidemic affected the risk behaviors of people who inject drugs in a city with high harm reduction service coverage in Vietnam? A qualitative investigation. Harm Reduct J. 2022;19(1):1–10. https://doi.org/10.1186/s12954-021-00586-1.

21. Schofield J, Dumbrell J, Matheson C, Parkes T, Bancroft A. The impact of COVID-19 on access to harm reduction, substance use treatment and recovery services in Scotland: a qualitative study. BMC Public Health. 2022;22(1):1–10. https://doi.org/10.1186/s12889-022-12873-y.

22. Rodda SN, Park JJ, Wilkinson-meyers L, King DL. The impact of COVID-19 on addiction treatment in New Zealand. Addict Behav. 2022;127:107230.

23. Aronowitz SV, Engel-rebitzer E, Lowenstein M, Meisel Z, Anderson E, South E. "We have to be uncomfortable and creative": reflections on the impacts of the COVID-19 pandemic on overdose prevention, harm reduction & homelessness advocacy in Philadelphia. SSM Qual Res Health. 2021;1:100013.

24. Davitadze A, Meylakhs P, Lakhov A, King EJ. Harm reduction via online platforms for people who use drugs in Russia: a qualitative analysis of web outreach work. Harm Reduct J. 2020;17(1):1–9. https://doi.org/10.1186/s12954-020-00452-6.

25. Uscher-Pines L, Sousa J, Raja P, Mehotra A, Barnett M, Huskamp HA. Treatment of opioid use disorder during COVID-19: experiences of clinicians transitioning to telemedicine. J Subst Abuse Treat. 2020;118:108124.

26. Vacciniasaing B, Mohd Salleh NA, Chooi WT, Singh D, Mohd Zaharin N, Kamarulzaman A, et al. COVID-19 impact on healthcare and supportive services for people who use drugs (PWUDs) in Malaysia. Front Psychiatry. 2021;12:630730.

27. Levander KA, Hoffman KA, McIvreen JW, McCarty D, Terashima JR, Korthuis PT. Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis. Addict Sci Clin Pract. 2021;16(1):1–10. https://doi.org/10.1186/s13732-021-00281-3.

28. Chiappini S, Guirguis A, John A, Corkery JM, Schifano F. COVID-19: the hidden impact on mental health and drug addiction. Front Psychiatry. 2020;11:767.

29. Kumar N, Janmohamed K, Nytran K, Martins SS, Cerda M, Wazaify M, et al. Substance, use in relation to COVID-19: a scoping review. Addict Behav. 2022;127:107213.

30. Martin R, Kang AW, De Britz AA, Walton MR, Hoadley A, Delacuesta C, et al. Medication for opioid use disorder service provision and telephone counseling: a concurrent mixed-methods approach. Int J Environ Res Public Health. 2021;18(11):16163.

31. Searby A, Burr D. Telehealth during COVID-19: the perspective of alcohol and other drug nurses. J Adv Nurs. 2021;77(9):3820–41.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress. Learn more: biomedicalcentral.com/submissions